Tag: Oregon Business
‘Finding Mold in a New Home’ – New Infographic Demonstrates How to Check for Mold Before It’s Too Late
PORTLAND, Ore., May 9, 2019 (SEND2PRESS NEWSWIRE) -- Mold Inspection Sciences (MIS), one of the state's largest mold inspection and testing companies, has announced the publication of an infographic now available to view and download from the Mold Inspection Sciences website.
Paragon BioTeck, Inc. Hosts Pearl Buck Preschool Holiday Event
PORTLAND, Ore., Nov. 27, 2018 (SEND2PRESS NEWSWIRE) -- Paragon BioTeck announces holiday event, "A Night to Remember," scheduled Friday, Dec. 7, 2018 from 5:30 - 8 p.m. in Eugene, Ore. The event delivers a magical night of holiday sights and sounds for the families of Pearl Buck Preschool.
The City of Portland is anxious to bring additional cellular coverage to their citizens – RFP awarded to XG Communities
PORTLAND, Ore., April 2, 2018 (SEND2PRESS NEWSWIRE) -- XG Communities, a premier provider of wireless marketing plans and engineering services for cities and municipalities across the United States, has been awarded an exclusive wireless marketing agreement with the City of Portland.
Paragon BioTeck Calls Emerging Leaders to Apply for 2018 Ophthalmology Scholarship
PORTLAND, Ore., Oct. 2, 2017 (SEND2PRESS NEWSWIRE) -- Paragon BioTeck, Inc., a privately-held pharmaceutical and medical device company, today announced the call for the next Koch Kellan Scholar. The annual Koch Kellan Scholarship honors one outstanding graduate medical student committed to elevating the standard of eye care through social responsibility and a clinical, teaching, or research career in ophthalmology. A Paragon Gives initiative, the scholarship reinforces the fundamental mission of Paragon BioTeck to drive innovations to address unmet and underserved medical needs.
U.S. Patent Ruling Affirms Claim for Paragon BioTeck’s R-Phenylephrine Hydrochloride Formulation
PORTLAND, Ore., Nov. 21, 2016 (SEND2PRESS NEWSWIRE) -- Paragon BioTeck, Inc. announces a monumental ruling handed down by the United States Patent and Trademark Office (USPTO) affirming claims made by Paragon in the patent for its R-phenylephrine hydrochloride formulation. Paragon is a privately held pharmaceutical and medical device company specializing in the development and commercialization of ophthalmic pharmaceuticals, devices and therapies.
